Search Results

You are looking at 11 - 20 of 22 items for :

  • "carboplatin plus paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Thymomas and Thymic Carcinomas

David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99 [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 15 ): Abstract 8018 . 87. Venuta F Rendina EA Longo F . Long-term outcome after multimodality treatment for stage III thymic tumors

Full access

Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer

Ryan D. Gentzler and Jyoti D. Patel

treated with carboplatin plus paclitaxel with or without bevacizumab every 3 weeks for 6 cycles. Those in the bevacizumab arm who did not have disease progression continued on bevacizumab at 15 mg/kg every 3 weeks until disease progression or unacceptable

Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

.1038/nrclinonc.2010.43 20368727 39. Zhang P , Yin Y , Mo H , . Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced

Full access

Modern Approaches to Localized Cancer of the Esophagus

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

over surgery alone in esophageal and gastroesophageal junction adenocarcinoma and squamous cancer. 45 This trial also used a more contemporary chemotherapy regimen: weekly carboplatin plus paclitaxel. Preoperative therapy conferred a median 2-year

Full access

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective

Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, and Yiduo Zhang

JD , Paulus R , Komaki R , . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

, . Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial . Lancet Oncol 2014 ; 15 : 396 – 405 . 10.1016/S1470-2045(14)70049-X 24582486 172. Clamp

Full access

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli II, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Kari Kendra, Jayanthi Lea, Nita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole McMillian, and Sara Espinosa

JCOG0505 . J Clin Oncol 2015 ; 33 : 2129 – 2135 . 94. Lorusso D , Petrelli F , Coinu A , A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer . Gynecol

Full access

Occult Primary

David S. Ettinger, Mark Agulnik, Justin M. M. Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, Panagiotis M. Fidias, David Gierada, Jon P. Gockerman, Charles R. Handorf, Renuka Iyer, Renato Lenzi, John Phay, Asif Rashid, Leonard Saltz, Lawrence N. Shulman, Jeffrey B. Smerage, Gauri R. Varadhachary, Jonathan S. Zager, and Weining (Ken) Zhen

: 912 - 922 . 67 Briasoulis E Kalofonos H Bafaloukos D . Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study . J Clin Oncol 2000 ; 18 : 3101 - 3107 . 68 Greco FA Burris

Full access

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

the metastatic setting. 119 , 121 – 123 In the 2018 version of these guidelines, the panel added carboplatin plus paclitaxel as an option for initial treatment of patients with metastatic anal cancer. This regimen has been assessed in several small

Full access

Non–Small Cell Lung Cancer

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory

randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 105 Ohe Y Ohashi Y Kubota K . Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus